



Ref: Syn/CS/SE/Reg 30/2025-26/Aug/06

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

August 20, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
--	--

Sub: Change in Senior Management Personnel - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A (7) of Part A of Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you of the following changes in organization structure of the Company with effect from today i.e., August 20, 2025:

- a. Appointment of Ajay Tandon, Head of Strategy and Corporate Development as a member of the Executive Committee (Senior Management Personnel) of the Company
- b. Appointment of Gaurav Kushwaha, Chief Technology Officer as a member of the Executive Committee (Senior Management Personnel) of the Company
- c. Appointment of Dr. Mrinal Kammili, Head of Translational and Clinical Research as a member of the Executive Committee (Senior Management Personnel) of the Company
- d. Appointment of Dr. Subhendu Kumar, Head of Chemistry as a member of the Executive Committee (Senior Management Personnel) of the Company
- e. Appointment of Dr. Priyaranjan Pattanaik, Head of Biology as a member of the Executive Committee (Senior Management Personnel) of the Company

The details required in terms of Regulation 30, Schedule III of the SEBI Listing Regulations and SEBI Circulars issued in this regard, are given in **Annexure – A**.

The above information will also be made available on the website of the Company at www.syngeneintl.com.



Kindly take the above information on record.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Chethan Yogesh

Company Secretary & Compliance Officer

Encl: a/a

Details as required under Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are as under:

S. No.	Particulars	Ajay Tandon
1.	Reason for change (viz. appointment, re-appointment , resignation, removal , death or otherwise)	Appointment of Ajay Tandon, Head of Strategy and Corporate Development as a member of the Executive Committee (Senior Management Personnel) of the Company
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment ;	Effective from August 20, 2025
3.	Brief profile	Ajay Tandon brings more than 30 years of leadership experience spanning life sciences, private equity, and banking. He focuses on envisioning business potential, strategic planning, and managing execution. Driven by a passion for innovation and growth, he thrives on engaging with people, ideas, and challenges. Renowned for his integrity and perseverance, Ajay cultivates enduring, trust-based relationships.
4.	Disclosure of relationship (in case of appointment)	Not Applicable

S. No.	Particulars	Gaurav Kushwaha
1.	Reason for change (viz. appointment, re-appointment , resignation, removal , death or otherwise)	Appointment of Gaurav Kushwaha, Chief Technology Officer as a member of the Executive Committee (Senior Management Personnel) of the Company.
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment ;	Effective from August 20, 2025
3.	Brief profile	Gaurav Kushwaha is a digital transformation leader with more than twenty years of experience across telecom, banking, Defense, pharma, chemicals, and manufacturing. He specializes in designing and implementing IT and digital strategies that drive EBITDA impact, reduce costs, and enhance business processes, earning over 20 global recognitions, including DEMING and Lighthouse awards.
4.	Disclosure of relationship (in case of appointment)	Not Applicable

Syngene

S. No.	Particulars	Dr. Mrinal Kammili
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Appointment of Dr. Mrinal Kammili, Head of Translational and Clinical Research as a member of the Executive Committee (Senior Management Personnel) of the Company.
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment ;	Effective from August 20, 2025
3.	Brief profile	Dr. Mrinal Kammili is a senior healthcare professional with more than 27 years of experience across healthcare, pharmaceuticals, clinical research, and life sciences. As a medical doctor, PhD holder, and AHA-qualified intensivist, he blends clinical expertise with strong leadership to foster organizational growth and deliver client-centric value.
4.	Disclosure of relationship (in case of appointment)	Not Applicable

S. No.	Particulars	Dr. Subhendu Kumar
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Appointment of Dr. Subhendu Kumar, Head of Chemistry as a member of the Executive Committee (Senior Management Personnel) of the Company.
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment ;	Effective from August 20, 2025
3.	Brief profile	Dr. Subhendu Kumar is an experienced medicinal chemist specializing in GPCR and oncology drug discovery. He has successfully led CRO projects involving more than 20 chemists to deliver lead-optimized candidates and possesses extensive experience in library synthesis of over 1,000 compounds. His expertise covers organic and medicinal chemistry, biology, ADMET, and drug discovery, supported by strong communication skills and collaborative leadership.
4.	Disclosure of relationship (in case of appointment)	Not Applicable

Syngene

S. No.	Particulars	Dr. Priyaranjan Pattanaik
1.	Reason for change (viz. appointment, re-appointment, resignation, removal, death or otherwise)	Appointment of Dr. Priyaranjan Pattanaik, Head of Biology as a member of the Executive Committee (Senior Management Personnel) of the Company.
2.	Date of appointment/ re-appointment /cessation (as applicable) & term of appointment/ re-appointment ;	Effective from August 20, 2025
3.	Brief profile	Dr. Priyaranjan Pattanaik, Ph.D., is a seasoned scientist and business leader with over 23 years of experience in pharmaceuticals and biotech within the CRO/CDMO space. With deep expertise in biotherapeutics—including antibodies, bispecifics, ADCs, peptides, proteins, and cell/gene therapies—he has led programs from discovery through clinical development. A passionate mentor and advocate for innovation, he brings strong scientific leadership and talent development skills.
4.	Disclosure of relationship (in case of appointment)	Not Applicable